A capsule-based scaffold incorporating decellularized extracellular matrix and curcumin for islet beta cell therapy in type 1 diabetes mellitus.

Ma, H; Xu, J; Fang, H; Su, Y; Lu, Y; Shu, Y; Liu, W; Li, B; Cheng, YY; Nie, Y; Zhong, Y; Song, K

A capsule-based scaffold incorporating decellularized extracellular matrix and curcumin for islet beta cell therapy in type 1 diabetes mellitus.

Ma, H Xu, J Fang, H Su, Y Lu, Y Shu, Y Liu, W Li, B Cheng, YY Nie, Y Zhong, Y Song, K

Permalink

Publisher:: IOP Publishing
Publication Type:: Journal Article
Citation:: Biofabrication, 2024, 16, (4), pp. 045038-045038
Issue Date:: 2024-09-19

In Progress

	Filename	Description	Size
	Ma_2024_Biofabrication_16_045038.pdf	Published version	7.86 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is being processed and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ma, H
dc.contributor.author	Xu, J
dc.contributor.author	Fang, H
dc.contributor.author	Su, Y
dc.contributor.author	Lu, Y
dc.contributor.author	Shu, Y
dc.contributor.author	Liu, W
dc.contributor.author	Li, B
dc.contributor.author	Cheng, YY
dc.contributor.author	Nie, Y
dc.contributor.author	Zhong, Y
dc.contributor.author	Song, K
dc.date.accessioned	2025-01-12T23:50:32Z
dc.date.available	2024-09-10
dc.date.available	2025-01-12T23:50:32Z
dc.date.issued	2024-09-19
dc.identifier.citation	Biofabrication, 2024, 16, (4), pp. 045038-045038
dc.identifier.issn	1758-5082
dc.identifier.issn	1758-5090
dc.identifier.uri	http://hdl.handle.net/10453/183284
dc.description.abstract	The transplantation of islet beta cells offers an alternative to heterotopic islet transplantation for treating type 1 diabetes mellitus (T1DM). However, the use of systemic immunosuppressive drugs in islet transplantation poses significant risks to the body. To address this issue, we constructed an encapsulated hybrid scaffold loaded with islet beta cells. This article focuses on the preparation of the encapsulated structure using 3D printing, which incorporates porcine pancreas decellularized extracellular matrix (dECM) to the core scaffold. The improved decellularization method successfully preserved a substantial proportion of protein (such as Collagen I and Laminins) architecture and glycosaminoglycans in the dECM hydrogel, while effectively removing most of the DNA. The inclusion of dECM enhanced the physical and chemical properties of the scaffold, resulting in a porosity of 83.62% ± 1.09% and a tensile stress of 1.85 ± 0.16 MPa. In teams of biological activity, dECM demonstrated enhanced proliferation, differentiation, and expression of transcription factors such as Ki67, PDX1, and NKX6.1, leading to improved insulin secretion function in MIN-6 pancreatic beta cells. In the glucose-stimulated insulin secretion experiment on day 21, the maximum insulin secretion from the encapsulated structure reached 1.96 ± 0.08 mIU ml-1, representing a 44% increase compared to the control group. Furthermore, conventional capsule scaffolds leaverage the compatibility of natural biomaterials with macrophages to mitigate immune rejection. Here, incorporating curcumin into the capsule scaffold significantly reduced the secretion of pro-inflammatory cytokine (IL-1β, IL-6, TNF-α, IFN-γ) secretion by RAW264.7 macrophages and T cells in T1DM mice. This approach protected pancreatic islet cells against immune cell infiltration mediated by inflammatory factors and prevented insulitis. Overall, the encapsulated scaffold developed in this study shows promise as a natural platform for clinical treatment of T1DM.
dc.format	Electronic
dc.language	eng
dc.publisher	IOP Publishing
dc.relation.ispartof	Biofabrication
dc.relation.isbasedon	10.1088/1758-5090/ad7907
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	0903 Biomedical Engineering, 1004 Medical Biotechnology, 1099 Other Technology
dc.subject.classification	3206 Medical biotechnology
dc.subject.classification	4003 Biomedical engineering
dc.subject.mesh	Animals
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Tissue Scaffolds
dc.subject.mesh	Curcumin
dc.subject.mesh	Mice
dc.subject.mesh	Decellularized Extracellular Matrix
dc.subject.mesh	Swine
dc.subject.mesh	Islets of Langerhans Transplantation
dc.subject.mesh	Capsules
dc.subject.mesh	Insulin
dc.subject.mesh	Diabetes Mellitus, Experimental
dc.subject.mesh	Cell Line
dc.subject.mesh	Extracellular Matrix
dc.subject.mesh	Cell Line
dc.subject.mesh	Extracellular Matrix
dc.subject.mesh	Animals
dc.subject.mesh	Swine
dc.subject.mesh	Mice
dc.subject.mesh	Diabetes Mellitus, Experimental
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Curcumin
dc.subject.mesh	Insulin
dc.subject.mesh	Capsules
dc.subject.mesh	Islets of Langerhans Transplantation
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Tissue Scaffolds
dc.subject.mesh	Decellularized Extracellular Matrix
dc.subject.mesh	Animals
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Tissue Scaffolds
dc.subject.mesh	Curcumin
dc.subject.mesh	Mice
dc.subject.mesh	Decellularized Extracellular Matrix
dc.subject.mesh	Swine
dc.subject.mesh	Islets of Langerhans Transplantation
dc.subject.mesh	Capsules
dc.subject.mesh	Insulin
dc.subject.mesh	Diabetes Mellitus, Experimental
dc.subject.mesh	Cell Line
dc.subject.mesh	Extracellular Matrix
dc.title	A capsule-based scaffold incorporating decellularized extracellular matrix and curcumin for islet beta cell therapy in type 1 diabetes mellitus.
dc.type	Journal Article
utslib.citation.volume	16
utslib.location.activity	England
utslib.for	0903 Biomedical Engineering
utslib.for	1004 Medical Biotechnology
utslib.for	1099 Other Technology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Institute of Biomedical Materials and Devices (IBMD)
utslib.copyright.status	in_progress	*
dc.date.updated	2025-01-12T23:50:30Z
pubs.issue	4
pubs.publication-status	Published online
pubs.volume	16
utslib.citation.issue	4

Abstract:

The transplantation of islet beta cells offers an alternative to heterotopic islet transplantation for treating type 1 diabetes mellitus (T1DM). However, the use of systemic immunosuppressive drugs in islet transplantation poses significant risks to the body. To address this issue, we constructed an encapsulated hybrid scaffold loaded with islet beta cells. This article focuses on the preparation of the encapsulated structure using 3D printing, which incorporates porcine pancreas decellularized extracellular matrix (dECM) to the core scaffold. The improved decellularization method successfully preserved a substantial proportion of protein (such as Collagen I and Laminins) architecture and glycosaminoglycans in the dECM hydrogel, while effectively removing most of the DNA. The inclusion of dECM enhanced the physical and chemical properties of the scaffold, resulting in a porosity of 83.62% ± 1.09% and a tensile stress of 1.85 ± 0.16 MPa. In teams of biological activity, dECM demonstrated enhanced proliferation, differentiation, and expression of transcription factors such as Ki67, PDX1, and NKX6.1, leading to improved insulin secretion function in MIN-6 pancreatic beta cells. In the glucose-stimulated insulin secretion experiment on day 21, the maximum insulin secretion from the encapsulated structure reached 1.96 ± 0.08 mIU ml-1, representing a 44% increase compared to the control group. Furthermore, conventional capsule scaffolds leaverage the compatibility of natural biomaterials with macrophages to mitigate immune rejection. Here, incorporating curcumin into the capsule scaffold significantly reduced the secretion of pro-inflammatory cytokine (IL-1β, IL-6, TNF-α, IFN-γ) secretion by RAW264.7 macrophages and T cells in T1DM mice. This approach protected pancreatic islet cells against immune cell infiltration mediated by inflammatory factors and prevented insulitis. Overall, the encapsulated scaffold developed in this study shows promise as a natural platform for clinical treatment of T1DM.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/183284